Mutational activation of FGFR3 is not involved in the development of prostate cancer

Pathobiology

Volumn 77, Issue 5, 2010, Pages 249-252

  Koufou, Stella ^a   Lunz, Jens Claudio ^b   Borchardt, Albert ^c   Keck, Bastian ^c   Kneitz, Burkhard ^d   Gaisa, Nadine T ^e   Hafner, Christian ^a   Giedl, Christian ^a   Rau, Tilman T ^c   Rogler, Anja ^c   Wieland, Wolf F ^a   Hartmann, Arndt ^c   Stoehr, Robert ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Group Practice for General Medicine   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

FGFR3; Incidental prostate cancer; Prostate cancer

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER GRADING; CANCER PATIENT; CARCINOGENESIS; COMORBIDITY; CONTROLLED STUDY; DNA ISOLATION; GENE MUTATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 78649812966     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317055     Document Type: Article

References (23)

1. Grose R, Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005;16:179-186.
2. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, Leung HY: Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-327.
3. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ: Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007;213:82-90.
4. Valta MP, Tuomela J, Bjartell A, Valve E, Väänänen HK, Härkönen P: FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 2008;123:22-31.
5. Capellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastra-Garau X, Chopin D, Thiery JP, Radnanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
6. Hafner C, van Oers JM, Hartmann A, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Vogt T: High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 2006;126:2404-2407.
7. Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A: Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006;116:2201-2207.
8. Knowles MA: Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;25:581-593.
9. Tomlinson DC, Baldo O, Harnden P, Knowles MA: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-98.
10. Boget S, Cereser C, Parvaz P, Leriche A, Revol A: Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not. Eur J Endocrinol 2001;145:303-310.
11. Naimi B, Latil A, Berthon P, Cussenot O: No evidence for fibroblast growth factor receptor 3. (FGFR-3) R248C/S249C mutations in human prostate cancer. Int J Cancer 2000;87:455-456.
12. Sibley K, Stern P, Knowles MA: Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumors. Oncogene 2001;20:4416-4418.
13. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-351. (Pubitemid 46328493)
14. Hernández S, de Muga S, Agell L, Juanpere N, Esgueva R, Lorente JA, Nojal S, Serrano S, Lloreta J: FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol 2009;22:848-856.
15. Sobin LH, Wittekind C: TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002.
16. Eble J, Sauter G, Epstein JI, Sesterhenn IA (eds): Classification of Tumours. Pathology and Gentics of Tumours of the Urinary System and Male Genital organs. Lyon, World Health Organization, 2004.
17. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC: A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005;11:7743-7748.
18. Zhang Y, Hiraishi Y, Wang H, Sumi K, Hayashido Y, Toratani S, Kan M, Sato JD, Okamoto T: Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 2005;117:166-168.
19. Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, Hartmann A, Hofstaedter F, Dietmaier W: Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 2008;39:126-136.
20. Singh A, Kinoshita Y, Rovito PM, Landas S, Silberstein J, Nsouli I, Wang CY, Haas GP: Higher than expected association of clinical prostate and bladder cancers. J Urol 2005;173:1526-1529.
21. Zhang H, Bermejo JL, Sundquist J, Hemminki K: Prostate cancer as a first and second cancer: effect of familial history. Br J Cancer 2009;101:935-939.
22. Hafner C, Vogt T, Hartmann A: FGFR3 mutations in benign skin tumors. Cell Cycle 2006;5:2723-2728.
23. Goriely A, Hansen RM, Taylor IB, Olesen IA, Jacobsen GK, McGowan SJ, Pfeifer SP, et al: Activating mutations in FGFR3 and HRAS revealed a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 2009;41:1247-1252.